ORIC Pharmaceuticals stock gains 12.10 percent at EUR 12.32

Published on 10/20/2026 at 19:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JPMorgan set a USD 26.00 target on October 14. ORIC Pharmaceuticals stock costs EUR 12.32 on October 20, 2026, up 12.10 percent versus Tradegate.

Price and analyst target

ORIC Pharmaceuticals stock gained 12.10 percent on October 20, 2026.
JPMorgan raised its target from USD 23.00 to USD 26.00 on October 14, 2026.
ORIC Pharmaceuticals stock costs EUR 12.32 at Lang & Schwarz on October 20, 2026 at 7:09 p.m. CEST, 12.10 percent above the Tradegate close of October 16, 2026.
ORIC reported a USD 41.49 million GAAP net loss for the quarter ended June 30, 2026.

ORIC, US68622P1093, Illustration mit AI erstellt.

ORIC Pharmaceuticals (ISIN US68622P1093) was trading at EUR 12.32 at Lang & Schwarz on October 20, 2026 at 7:09 p.m. CEST, up 12.10 percent versus the Tradegate close of October 16, 2026. MarketBeat reported that JPMorgan raised its target from USD 23.00 to USD 26.00 on October 14, 2026 and maintained an Overweight rating.

JPMorgan target reaches USD 26.00

The new target is USD 13.00 above the current Nasdaq quote of USD 13.00? No. The latest structured Nasdaq quote was USD 13.90 at 1:16 p.m. ET on October 20, 2026. Against that price, the USD 26.00 target stands 87.05 percent higher, using the same currency. The target change itself was 13.04 percent from USD 23.00.

USD 13.90 sits below the high

ORIC traded between USD 12.52 and USD 14.28 during the October 20, 2026 Nasdaq session. Its 52-week range was USD 7.23 to USD 14.68, placing the latest USD 13.90 quote 5.31 percent below the high. Volume reached 1,008,429 shares, while market capitalization stood at USD 1.4 billion on October 20, 2026.

Second-quarter loss reaches USD 41.49 million

For the quarter ended June 30, 2026, ORIC reported a GAAP net loss of USD 41.49 million, compared with USD 36.36 million in the year-earlier quarter, according to Markets Insider. The company also posted a GAAP loss of USD 0.38 per share, missing the cited consensus estimate of USD 0.36 per share.

Clinical pipeline remains central

ORIC describes itself as a clinical-stage biopharmaceutical company developing therapies intended to overcome resistance in cancer, according to its investor-relations page. Its October 5, 2026 release identified a collaboration with Cancer Research UK to advance a potential CIP2A-targeted therapy into clinical development.

Price and target in perspective

The market price remains well below the latest analyst targets, but the recent quarterly loss underlines the clinical and financial risk attached to a development-stage biotechnology company.

The further course of trading is shown by the continuously updated real-time quote of ORIC Pharmaceuticals stock.